The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I clinical trial of stereotactic body radiotherapy with atezolizumab and bevacizumab in advanced hepatocellular carcinoma.
 
Timothy J Brown
No Relationships to Disclose
 
Andy J Minn
No Relationships to Disclose
 
Erica L. Carpenter
Honoraria - AstraZeneca; Guardant Health
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - AstraZeneca (Inst); Becton Dickinson (Inst); C2i genomics (Inst); Chip Diagnostics (Inst); Janssen (Inst); Merck (Inst); Merck (Inst); Parker Institute for Cancer Immunotherapy (Inst); United Health Group
Patents, Royalties, Other Intellectual Property - Invention disclosure entitled, "Methods and Compositions for Identifying, Diagnosing and Treating Neuroblastoma"; Invention disclosure entitled, "Methods and Compositions for Identifying, Diagnosing and Treating Neuroblastoma"; Invention disclosure entitled, "Methods and Compositions for Treating Neuroblastoma"
Travel, Accommodations, Expenses - AstraZeneca; Foundation Medicine
 
Edgar Ben-Josef
No Relationships to Disclose
 
Thomas Benjamin Karasic
Honoraria - AstraZeneca/MedImmune; Exelixis; Incyte; Ipsen; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); H3 Biomedicine (Inst); Lilly (Inst); Sirtex Medical (Inst); Syndax (Inst); Taiho Pharmaceutical (Inst); Tempest Therapeutics (Inst); Xencor (Inst)